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Influenza epidemics continue to be a major
cause of excessive winter morbidity and mortality,
particularly in elderly individuals. Immunisation
against influenza has been shown to be effective in
reducing serious complications in high-risk pa-
tients [1–3]. In addition, it is well established that
influenza vaccination is a cost effective measure
[4–8]. During the 1999–2000 epidemic, 447 sus-
pected cases of influenza were reported in Switzer-
land by the Swiss Sentinel Surveillance Network
[9]. The National Influenza Centre received 653
samples during the same epidemic, of which 26%
were confirmed to be influenza A. This figure rose
to as much as 46% among people over 70 years of
age [10]. International cooperation is important in
such public health campaigns and Switzerland
takes part in the European Influenza Surveillance
System [11].
Influenza vaccination is now better accepted
by the general public, as well as within the medical
community. Several studies in Europe and North
America have shown appropriate immunisation
coverage among target groups [12–16]. In Switzer-
land, a recent study showed that 78% of medical
doctors consider the immunisation as a public
health priority [17]. In an other study, including
target group patients, 8% were vaccinated in hos-
pital and 55% by their medical practitioner [18].
In 1993, Barazzoni found that influenza vaccina-
tion coverage among institutionalised elderly peo-
ple in the canton of Ticino, varied between 48%
and 61% [19]. In a recent study among people
older than 60, vaccine coverage was found to be
51% in the French speaking part of Switzerland,
whereas it was lower in the German and Italian
speaking cantons (41% and 38%, respectively)
Introduction: Influenza is a major cause of mor-
bidity and mortality and occurs in epidemics in the
winter. This study is an evaluation of a population-
based prevention program against Influenza,
implemented during autumn 2000 by the Health
Department of the Canton of Vaud. 
Methods: A pre-intervention/post-interven-
tion design was used. In June 2000 and March
2001, 4007 questionnaires were sent to two differ-
ent stratified random samples of people aged 65
and over living in the Canton of Vaud, Switzerland.
Univariate, bivariate and multivariate analyses
were performed.
Results: Vaccination coverage among people
older than 65 was 58.0% in 1999 (95% CI: 56.2%–
59.8%) and 58.4% (95% CI: 56.6%–60.2%) in
2000. A 6.5% significant increase in vaccination
coverage was seen in the group of people aged 65
to 69 (p = 0.008). In the pre-intervention survey
immunisation rates were 22.6% among people
who had not consulted a physician, 59.2% among
those who had consulted a physician once, and
73.2% among those who consulted twice or more
(p = 0.001). These rates were respectively 30.8%,
58.0% and 75.1% (p = 0.001) in the post-inter-
vention survey.
Conclusions: No global increase in Influenza
vaccination coverage in the elderly population
could be observed following a community based
intervention in a Swiss Canton. However, the en-
hanced vaccination rates noted in the 65–69 years
old group and in people who did not receive med-
ical care are compatible with an effect of the cam-
paign. Further increase in vaccination coverage
may be obtained by diversification and repetition
of such promotion campaigns. 
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[20]. These figures are substantially below the cor-
respondent coverage in neighbouring countries.
In autumn 2000, the Health Department of
the Canton of Vaud implemented a population-
based influenza prevention program among peo-
ple older than 65. The aim of this program was to
improve the image of the vaccination among the
target population [21], in particular the awareness
and knowledge about influenza and immunisation
by involving health professionals. A secondary ob-
jective was to improve vaccination coverage in the
elderly population. The project used the local
health services network in the Canton of Vaud: the
Health Department, the medical-social services,
the medical outpatient clinics, health leagues, the
cantonal associations of physicians and pharma-
cists, etc. Clubs and Associations for elderly peo-
ple were also involved to improve vaccination cov-
erage. The main activities of the project, were in-
formation-meetings about influenza vaccination
among associations for the elderly (eg, Pro-Senec-
tute), and for the staff of socio-medical institutions
and services. Information tools were developed,
such as a video, information leaflets, brochures, ar-
ticles in the lay press, a website and a press-con-
ference. In addition, information was transmitted
by the local TV-network. 
The aim of this study was to evaluate the im-
pact of this population-based prevention program:
“Un plus pour les SENIORS: la vaccination contre la
grippe”. Secondary aims of the study were to assess
which sub-groups responded best to the program,
which component of the program had the most im-
pact, and which factors were predictors of vacci-
nation coverage. 
Methods 
A pre-intervention/post-intervention design was
chosen to assess the impact of the population-based pre-
vention of influenza program, among 96’657 people over
the age of 65, living in the Canton of Vaud, Switzerland.
The pre-intervention vaccination coverage survey was
performed during the summer of 2000. Following that,
the population-based prevention program took place in
the autumn of 2000, and finally, the post-intervention
survey was done during the spring of 2001. 
Studied population
In June 2000, 4007 questionnaires were sent for the
pre-intervention survey to people older than 65, living in
the Canton of Vaud. This population was selected using a
random sample, stratified by age categories and civil sta-
tus of the elderly population. After two weeks, a reminder
card was sent to all recipients, followed by a second and 
a third questionnaire after, respectively, one and two
months, if the person had not responded to the previous
mailings. The same procedure was used for the second sur-
vey in 2001. A different sample was randomly selected, and
4007 questionnaires were sent in March 2001.
Data entry was repeated for a random sample of 100
questionnaires, to assess its quality. Errors were found in
0.29% (95% CI: 0.11%–0.47%) of double-entered ques-
tionnaires. 
Questionnaire
The questionnaires were developed in collaboration
by the Health Department of the Canton of Vaud, and the
Institute for Social and Preventive Medicine, University
of Lausanne. Questions about immunisation, influence
and motivation for vaccination, and reasons for its refusal
were included, as well as questions related to predictive
factors to the vaccination, such as demographic or socio-
economic characteristics and contact with medical doctors
or social services during the fall. The questionnaire used
for the post-intervention survey in 2001 was shorter, and
included the same items and also questions about the
impact of the prevention program. In both surveys, if a
person refused to participate in the study, the main reason
for this refusal was requested.
Statistical analysis
In both surveys, we first carried out a descriptive, uni-
variate analysis of all the variables. In addition in the first
survey, bivariate and multivariate analyses were con-
ducted, to assess the role of the different predictors in re-
lation to the vaccination. For the bivariate analysis, chi-
square tests were implemented. For the multivariate
analysis, a logistic regression analysis was performed. A
backward elimination procedure was used to find the best-
fitting model [22]. Interaction variables were dropped
from the model, because none were statistically signifi-
cant. However the variable “sex”, also not significant, was
considered as a possible confounding factor and kept in
the model. All the analyses were done using the SAS soft-
ware (SAS Institute Inc., Cary, NC, USA). 
Results
Out of 4007 questionnaires which were sent
out in the pre-intervention survey, 137 of the re-
sponders were ineligible, 29 returned incomplete,
908 individuals refused to participate and 2933
were completed and returned (participation rate:
75.8% (2933/3870 eligible). In the post-interven-
tion survey, 4007 questionnaires were sent out, 182
persons were ineligible, 228 returned incomplete,
499 of the study group refused to participate and
3098 were completed and returned (participation
rate: 81.0% (3098/3825 eligible). We further ex-
cluded two persons in the first survey and six in the
second, because they were less than 65 years old.
In the pre-intervention survey 31.3% of the per-
sons who refused to participate stated their main
reasons for not participating. These were: “lacking
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interest” for 51.8%, “questions too personal” for
7.4%, “unable to answer” for 6.7%, “momentarily
not available” for 4.9%, “does not understand
French” for 3.9%, “no time” for 2.1% and “other
reasons” for 42.3%. 
In the 2000 pre-intervention survey the mean
age was 74.7 years and in the 2001 post-interven-
tion survey 74.3 years. Table 1 describes patients’
characteristics in both surveys (2000 and 2001).
Vaccination coverage
Results from the pre-intervention survey im-
plemented in 2000 showed that the vaccination
coverage among people older than 65 living in the
Canton of Vaud was 58.0% in 1999 (95% CI:
56.2%–59.8%). In the post-intervention survey
done in 2001, the vaccine coverage in 2000, among
the same population, was 58.4% (95% CI: 56.6%–
60.2%).
In 1999 vaccination rates were 58.6% for men,
and 57.8% for women (p = 0.672). In 2000 the rates
were 58.9% for men, and 58.2% for women (p =
0.717). 
Impact of the programme
Table 2, shows that vaccination coverage in-
creased with age, until age 90, in both surveys.
Overall, vaccination coverage was similar in 1999
and in 2000 (p = 0.757). However, a significant in-
crease (6.5%) in vaccination coverage was ob-
served in the sub-group of people aged 65 to 69 
(p = 0.008). 
Figure 1 shows that in 1999, vaccination rates
were 22.6% among people who did not consult a
physician, 59.2% among those who had consulted
a physician once and 73.2% among those who had
consulted twice or more during in the autumn.
The difference between the three groups was sta-
tistically significant (p = 0.001). For the vaccina-
tion rate in 2000, these figures were respectively
30.8% for those who had never consulted a physi-
cian, 58.0% for those who had consulted once, and
75.1% for those who had consulted twice or more.
The difference between the three categories was
also statistically significant (p = 0.001). The im-
munisation coverage was 74.7% among those who
had had a home visit from a social worker (nurse
or other family-help), and 55.4% among those
who had not (p = 0.001). In 2000, these figures
were respectively 76.0% and 56.0% (p = 0.001). 
52.7% of all the respondents in the post-in-
tervention survey (older than 65 living in the Can-
ton of Vaud) knew about the program. The pro-
gram ‘SENIORS +’ used different tools to increase
vaccination coverage. The brochure “La grippe se
sert de vous” was the tool which had the most im-
pact (28.7%) (table 3).
During the post-intervention survey, 69.5% of
Patients pre-intervention post-intervention 
characteristics survey 2000 survey 2001 
N (%) N (%)
Age group 65–69 years 805 (28.0) 877 (29.0)
70–74 years 723 (25.2) 792 (26.2)
75–79 years 638 (22.2) 692 (22.9)
80–84 years 410 (14.3) 396 (13.1)
85–89 years 242 (8.4) 190 (6.3)
≥90 years 54 (1.9) 74 (2.4)
Sex men 1272 (44.2) 1330 (43.8)
women 1606 (55.8) 1704 (56.2)
Visit to a physician none 575 (20.8) 737 (25.6)
during the fall one 955 (34.6) 883 (30.6)
two or more 1228 (44.6) 1262 (43.8)
Medico-social service visit 224 (8.3) 245 (8.5)
no visit 2466 (91.7) 2651 (91.5)
Table 1
Patients characteris-
tics in the two
samples, N = 2931 in
2000 and N = 3092 
in 2001.
Age group survey 2000 survey 2001 difference between P value
vaccination 1999 vaccination 2000 surveys in%
N (%) N (%) 
65–69 years 316 (40.5) 401 (47.0) 6.5 0.008
70–74 years 409 (58.6) 439 (57.5) –1.1 0.682
75–79 years 410 (66.5) 424 (62.8) –3.7 0.172
80–84 years 274 (69.0) 271 (71.3) 2.3 0.484
85–89 years 167 (72.6) 126 (69.2) –3.4 0.452
≥90 years 32 (64.0) 47 (66.2) 2.2 0.803
Total 1608 (58.0) 1708 (58.4) 0.4 0.757
Table 2
Survey 2000 and
2001: vaccination
rate in 1999 
(N = 2872) and 2000
(N = 2924) per age
group.
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the participants declared themselves willing to
have the vaccination in autumn 2001. Intentions
for vaccination in 2001 were respectively 63.4%
for the group 65 to 69 years, 68.3% for the group
70 to 74 years, 71.1% for the group 75 to 79 years,
77.3% for the group 80 to 84 years, 76.5% for the
group 85 to 89 years, and 73.0% for people older
than 90 years. 
Motivations for or against vaccination
The different reasons that motivated people to
be vaccinated against influenza are listed in table
4. Receiving advice from a medical doctor was con-
sidered very important, and was associated with
vaccination coverage of 67.8% and 65.8% in the
pre and post-intervention survey respectively.
Reasons for not being vaccinated are described in
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Survey 2000 and
2001: vaccination
rate 1999 (N = 2664)
and 2000 (N = 2789)
and the frequency 
of visit to a physi-
cian.
Means N (%) * vaccination rate 
in 2000 in %
Brochure «la grippe se sert de vous» 441 (28.7) 63.1
Article published in a magazine («Générations») 335 (21.8) 59.3
Local TV (Autumn 2000) ** 309 (20.1) 59.8
TV-advertisement (“Miss Suisse”) 225 (14.7) 52.0
Advertisement of the programme SENIORS+ in the local press 154 (10.0) 47.7
Brochure with a letter from cantons “surgeon general” 153 (10.0) 48.7
Itinerant exhibition 51 (3.3) 63.3
Participation in a meeting of a group of elderly people 38 (2.5) 62.9
Video of the SENIORS+ program 33 (2.1) 76.7
Breakfast-contact in a trade fare (Pro-Senectute) 13 (0.8) 66.7
Website about the activities of the SENIORS+ program 6 (0.4) 0
Other ways 247 (16.1) 53.8
** Several answers were possible, the total might exceed 100%
** Local television in the region of Lausanne.
Table 3
Survey 2001: means
by which people had
acquired knowledge
about the SENIORS+
program, N = 1535.
Reasons for being vaccinated survey 2000: N (%) * survey 2001: N (%) *
Advice from a physician 1109 (67.8) 1149 (65.8)
Refusal of disease 372 (22.7) 374 (21.4)
Fear of Influenza 336 (20.5) 337 (19.3)
Scared to contaminate someone 157 (9.6) 183 (10.5)
Suffering chronic disease 147 (9.0) 173 (9.9)
Has numerous contacts 84 (5.1) 98 (5.6)
Other reasons 124 (7.6) 124 (7.1)
* Several answers were possible, the total might exceed 100%.
Table 4
Survey 2000 and
2001: motivation 
to be vaccinated, 
N = 1636 in 2000 and
N = 1746 in 2001.
Reasons for not being vaccinated survey 2000: N (%) * survey 2001: N (%) *
Not being afraid of influenza 368 (31.1) 387 (31.2)
Afraid about the side effects of the vaccine 318 (26.9) 296 (23.8)
Has not thought about vaccination 182 (15.4) 150 (12.1)
Do not believe the vaccine to be efficacious 155 (13.1) 160 (12.9)
Not concerned 111 (9.4) 114 (9.2)
No more vaccine available not asked 40 (3.2) **
Other reasons 259 (21.9) 246 (19.8)
* Several answers were possible, the total might exceed 100%.
** Question asked after global vaccine shortage in winter 2000–2001.
Table 5
Survey 2000 and
2001: reasons not 
to be vaccinated, 
N = 1183 in 2000, and
N = 1242 in 2001.
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table 5. In both surveys, the main reason was “not
being afraid of influenza”. 
Predictors for influenza vaccinations
Bivariate and multivariate analyses were con-
ducted using results of the 2000 pre-intervention
survey to determine which factors are predictors of
influenza immunisation. These results are pre-
sented in table 6. The adjusted odds ratio for the
different age categories, compared with people
aged 65 to 69 years, were all statistically significant.
The adjusted odds ratio was 2.52 (95% CI: 2.05–
3.10) for people who had consulted a physician
once, and 4.51 (95% CI: 3.65–5.57) for people
with two or more visits, compared with persons
who had not consulted a physician.
Predictors bivariate analysis multivariate analysis, N = 2579
crude RR 95% CI P adjusted OR 95% CI P
Age (N = 2772)
65–69 years 1.00 ref * 1.00 ref *
70–74 years 1.45 1.30–1.61 0.0001 1.96 1.57–2.46 0.0001
75–79 years 1.64 1.48–1.82 0.0001 2.62 2.06–3.33 0.0001
80–84 years 1.70 1.53–1.90 0.0001 2.85 2.15–3.78 0.0001
85–89 years 1.79 1.60–2.01 0.0001 3.29 2.29–4.73 0.0001
>90 years 1.58 1.26–1.98 0.001 1.77 0.94–3.33 0.078
Sex (N = 2776) 1.01 0.95–1.08 0.672 1.14 0.96–1.35 0.147
Visit to a physician (N = 2664)
None 1.00 ref * 1.00 ref *
One 2.62 2.23–3.09 0.0001 2.52 2.05–3.10 0.0001
Two or more 3.24 2.77–3.80 0.0001 4.51 3.65–5.57 0.0001
Used medico-social services (N = 2601) 1.35 1.24–1.47 0.0001 1.90 1.33–2.72 0.0004
* ref = reference group
Table 6
Survey 2000: Bivari-
ate and multivariate
analyses, predictors
of influenza vaccina-
tion.
Discussion
Influenza remains a major public health threat,
especially for individuals over 65 years [1–3]. In
particular, excess of mortality was estimated to be
between 43% to 65% among people older than 65
years in the US [21].
In autumn 2000 the Health Department of the
Canton of Vaud implemented a population-based
prevention program to improve influenza immu-
nisation coverage among elderly people. Results of
this evaluation study showed that overall, no in-
crease in vaccination coverage was observed be-
tween the two surveys (before and after the pro-
gram). Only a significant 6.5% absolute increase
was observed in the age-group from 65 to 69 years
of age, contrasting with not significant decrease
observed in other more vulnerable age groups. We
also showed an 8.2% absolute increase in people
who had not consulted a physician during the au-
tumn. These were, however, probably “healthy”
elderly individuals compared with those who con-
sulted several times. Among those persons who
were in the high-risk group, we observed almost
no changes. The prevention program seems to
have had an impact only on the elderly at low risk.
The population-based prevention program
‘SENIORS+’ seems to have had very good expo-
sure in the population, since 53% of the people in
the sample knew about it. A brochure (“La grippe
se sert de vous”) was the main element. Physicians
have an important role to play in motivating peo-
ple for influenza immunisation, as the main source
of motivation was advice received from a physician. 
Several obstacles for achieving higher vaccina-
tion coverage remain, including the fact that a
large minority of at-risk individuals fear secondary
effects of the vaccine, are either not afraid of in-
fluenza, or not convinced of the vaccine’s effec-
tiveness. The most important predicting factors
for influenza immunisation among elderly people
were age and medical visits during the autumn.
Physicians indeed play an important role for im-
proving immunisation rates. They ought to con-
tinue in this direction and promote influenza vac-
cination each autumn in the outpatient setting, in
nursing homes and even in hospitals.
The campaign was adequate and well de-
signed. It was important in particular to involve
health professionals. A similar campaign was then
implemented at the national level by the Swiss
Federal Office of Public Health, which included
lessons learned from the program in the canton of
Vaud [23].
The vaccination coverage observed in this
study among people older than 65 are comparable
to those described in other European- or North
American countries. For example, rates of 60%
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were reported in a study conducted in The
Netherlands [24], and 52% in a Canadian survey
[25]. In another study performed in the USA, in-
fluenza vaccination coverage was 58% among a
similar population [26]. Compared to vaccination
rates recently described in a study conducted in
Switzerland in adults aged 60 and over, our results
were higher than those observed in the German
and Italian speaking parts of the country, but sim-
ilar to the rates previously observed in the French
speaking part of country (51%) [20].
Although our study gave reliable results be-
cause we used a large random sample and obtained
a very high participation rate, several weaknesses
and limitations should be mentioned. First, a pre-
post-intervention design was chosen instead of a
randomised or a quasi-experimental trial. A con-
trol group could not be assembled for practical and
ethical reasons and it was impossible to conduct an
experiment using a control population in another
canton without performing an intervention. With
this design (two cross-sectional surveys), it was in
particular not possible to assess the causal associa-
tion with this prevention program and the vacci-
nation coverage. Secondly, we encountered some
difficulties with the address file used, which in-
cluded several mistakes (eg, people younger than
65, or people who had died). This source of data
was also not completely representative of the en-
tire population of the Canton of Vaud, because it
didn’t include elderly living in nursing homes, or
foreigners with Permit A and B. Third, it is possi-
ble that the increase of the vaccination coverage in
the 65–69 years age group between the two sur-
veys is due to a recall bias that might have occurred
among older age groups.
In conclusion, improvements of vaccination
rates in elderly people may be achieved through
implementation of a population-based prevention
program, such as SENIORS+. Such programs 
may have an impact on low risk young elderly
(65–69 years), who did not have any contact with
a physician. Also we didn’t observe a short term ef-
fect of the campaign, a long term effect might be
seen if we repeat the survey in 2 or 3 years. Fur-
ther increase in vaccination coverage may be ob-
tained by diversification and repetition of such
promotional campaigns, for instance the new cam-
paign [23] from the Swiss Federal Office of Public
Health.
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